Enzastaurin and Bevacizumab in Treating Patients With Locally Advanced or Metastatic Cancer

Part of paid clinical trials in Baltimore, Maryland.

Sponsor
Eli Lilly and Company
Study ID
NCT00550927
Phase
PHASE1
Status
Completed

Conditions

  • Unspecified Adult Solid Tumor, Protocol Specific

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • bevacizumab — BIOLOGICAL
  • enzastaurin hydrochloride — DRUG
  • diagnostic laboratory biomarker analysis — OTHER
  • pharmacological study — OTHER

Study Details

RATIONALE: Enzastaurin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Enzastaurin and bevacizumab may also stop the growth of cancer cells by blocking blood flow to the cancer. Giving enzastaurin together with bevacizumab may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of enzastaurin and bevacizumab in treating patients with locally advanced or metastatic cancer.

Key Dates

First listed
Oct 30, 2007
Start date
Nov 30, 2006
Status verified
Jun 2012
Primary completion
Mar 31, 2010
Completion
Sep 30, 2012

Study Design

Enrollment
42 participants (estimated)
Allocation
NON_RANDOMIZED
Primary purpose
TREATMENT

Primary Outcome Measure

Recommended phase II doses of enzastaurin hydrochloride and bevacizumab

Locations (1)

FacilityCityStateZIPSite coordinators
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsBaltimoreMaryland21231-2410-

Find similar trials in Baltimore, MD

By research site
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins· Baltimore, MD

Related Studies